- 30atm inflation device for angioplasty balloon deployment features a 25cc barrel, glow-in-the-dark gauge, simple locking mechanism and ergonomic plunger handle
- Designed for use in both coronary and peripheral interventions in U.S. and international markets
- Available packaged separately and in a variety of pre-configured interventional packs containing the Guardian® hemostasis valve and other angioplasty accessories
MINNEAPOLIS, Oct. 21, 2016 -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Fluent inflation device for use during cardiovascular procedures to create, maintain, and monitor pressure in balloon catheters. Fluent received CE Mark clearance in August 2016 and has already begun international clinical evaluations. Vascular Solutions expects to commence the commercial launch of Fluent in the U.S. and Europe during the fourth quarter.
“Every angioplasty procedure requires the use of an inflation device, and we are pleased that today’s FDA clearance to market Fluent will allow us to expand our presence in this large, yet competitive, market,” said Howard Root, Chief Executive Officer of Vascular Solutions. “The internally-developed and manufactured Fluent has design and performance characteristics that we believe will make it a popular choice for physicians who perform a wide range of interventional procedures, particularly when combined with Vascular Solutions’ widely-used Guardian hemostasis valves in a convenient interventional pack configuration.”
The Fluent inflation device features a 25cc barrel and creates pressures up to 30 atmospheres of mercury (atm). The ergonomic design provides a system that is easy to fill, flush, and operate. The locking mechanism is marked to show locked and unlocked positions. The pressure gauge glows in the dark so that it is easily readable under low light conditions in the cath lab.
Vascular Solutions will offer the Fluent inflation device in 10 configurations to meet a wide variety of procedural requirements: packaged separately and as a kit including the Guardian hemostasis valve and other angioplasty accessories.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company has launched more than 100 products that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2015 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone, VP Vascular Solutions, Inc. [email protected] (763) 656-4371


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 



